Several epidemiological studies on ataxia-telangiectasia families indicate that obligate ATM heterozygotes display an elevated risk for developing breast cancer. However, a molecular basis for a potential link between diminished ATM function and sporadic breast malignancy remains elusive. Here, we show that 78% (18 out of a panel of 23) of surgically removed breast tumors (stage II or greater) displayed aberrant methylation of the ATM proximal promoter region as judged by methylation-specific PCR. Aberrant methylation of the ATM promoter was independently confirmed in several tumors by bisulfite sequencing. Moreover, bisulfite sequencing indicated that this region of the genome is subject to dense methylation. Further, we found a highly significant correlation (P ¼ 0.0006) between reduced ATM mRNA abundance, as measured by realtime RT-PCR, and aberrant methylation of the ATM gene promoter. These findings indicate that epigenetic silencing of ATM expression occurs in locally advanced breast tumors, and establish a link at the molecular level between reduced ATM function and sporadic breast malignancy.
Germline mutation of the ATM gene is the underlying cause of the cancer-prone disorder ataxia-telangiectasia (A-T) (Rotman and Shiloh, 1998) . As outlined in the seminal work of Swift et al. (1987) , and validated in subsequent studies (Easton, 1994; Athma et al., 1996) , obligate ATM heterozygotes display an approximate fourfold elevated risk for developing breast cancer. Following the cloning of the ATM gene, several groups (FitzGerald et al., 1997; Bebb et al., 1999; Shafman et al., 2000) studied large cohorts of sporadic breast cancer patients and age-matched controls for nonsense or frame-shift mutations within the ATM gene. Neither group found evidence for a higher incidence of defective ATM alleles in the cancer patient cohort. Furthermore, the correlation between breast cancer and dominantnegative forms of ATM arising from defined missense or intronic mutations within the ATM gene remains controversial (Chenevix-Trench et al., 2002; Bernstein et al., 2003) . Thus, a potential role for diminished ATM function in sporadic breast cancer remains unresolved.
We have reported that, in cultured tumor cells, the ATM gene is subject to epigenetic silencing attributable to aberrant methylation of its proximal promoter region (Kim et al., 2002) . More recently, we determined that aberrant methylation of the ATM promoter occurs in a subset of head and neck tumors (Ai et al., 2004) . Further, several reports showed that reduced ATM expression, as judged by immunohistochemical staining, occurs in a significant portion of breast tumors (Kairouz et al., 1999; Angele et al., 2000) . Collectively, these findings led us to hypothesize that epigenetic events, rather than somatic mutation of the ATM gene itself, link reduced ATM function to sporadic breast cancer.
The putative proximal promoter of the ATM gene is a B520 bp intergenic region shared with the NPAT gene, which extends in the opposite orientation (Byrd et al., 1996) . We developed a methylation-specific PCR (MSP) assay (Herman et al., 1996) to analyse the methylation status of the ATM promoter in genomic DNA isolated from surgically obtained breast tumors. Oligonucleotide primers were designed to amplify a segment of the ATM promoter existing in either a methylated or unmethylated state based on the modification status of CpG dinucleotides following sodium bisulfite modification ( Figure 1a) . The primers designed to amplify unmethylated ATM promoter sequence yield a 179 bp amplicon spanning from nt# À441 to À263, and the methylated primer set yield a 178 bp amplicon spanning from nt# À441 to À264 (numbering system based on the location of the ATM translational start site).
To validate initially our designed MSP assay system, we tested these primers in PCR reactions using bisulfitemodified genomic DNA (gDNA) harvested from normal human diploid foreskin fibroblasts (NHF). Amplification of the ATM promoter from NHF gDNA was observed using the unmethylated (U)-specific primer set but not with the methylated (M)-specific primer set (Figure 1b, lanes 1 and 2) . When NHF gDNA was methylated in vitro using SssI methylase and subsequently subjected to bisulfite modification prior to PCR, we observed accumulation of the M-specific amplicon but not the U-specific product (Figure 1b , lanes 3 and 4). Furthermore, we observed that PCR reactions conducted on nonmethylated NHF gDNA that was not subjected to bisulfite modification prior to PCR failed to result in the accumulation of either U or M amplicons (Figure 1b , lanes 5 and 6), and similar results were obtained when PCR was conducted on in vitro methylated DNA that was not bisulfite-modified (data not shown).
Next, we tested these MSP primer sets using gDNA harvested from the colorectal tumor line HCT-116. We previously demonstrated, using a restriction enzymebased approach, that an isolate of this line displays aberrant methylation of the ATM proximal promoter region (Kim et al., 2002) . Analysis of bisulfite-modified HCT-116 gDNA with our MSP primer sets showed accumulation of the methylated-specific amplicon ( Figure 1c, lanes 1 and 2) . MSP conducted on bisulfite-modified gDNA isolated from HCT-116 cells cultured in the presence of the global demethylating agent 5-azacytidine showed accumulation of the unmethylated amplicon (Figure 1c, lanes 3 and 4) . Taken together, these stringent verification and validation experiments indicate that our MSP primers amplify genomic DNA in a manner that clearly ascertains the methylation status of the ATM promoter.
Subsequently, we analysed ATM promoter methylation status in 23 randomly chosen, surgically obtained human breast tumors. Fresh-frozen breast tumors were obtained from the LSU Health Sciences Center Tumor Bank and were treated in accordance with policies of the LSUHSC IRB. For this study, we chose to focus on . Bisulfite-modified NHF gDNA (lanes 1 and 2), NHF gDNA treated with SssI methylase (NEB) prior to bisulfite modification (lanes 3 and 4), nonbisulfite-modified NHF gDNA (lanes 5 and 6) or diH 2 O (lanes 7 and 8) was used in PCR reactions with the unmethylated-specific (U; lanes 1, 3, 5 and 7) or methylated-specific (M; lanes 2, 4, 6 and 8) MSP primer sets. (c) Bisulfite-modified gDNA harvested from HCT-116 cells (lanes 1 and 2) or HCT-116 cultured in the presence of 5-azacytidine (lanes 3 and 4) was used in MSP analysis. (d) Bisulfite-modified gDNA isolated from indicated breast tumors (lanes 1-14) was analysed by MSP. Bisulfite-modified HMEC gDNA (lanes 15 and 16) and CpGenomet Universal Methylated DNA (Chemicon; lanes 17 and 18) were also subjected to MSP analysis locally advanced tumors (stage II or greater) since malignancies of this size yielded sufficient material to conduct all of the studies outlined herein. Malignant cells were isolated by either laser-capture microdissection or, where feasible, manual microdissection of cryosectioned breast tumors. Subsequently, gDNA was extracted, bisulfite-modified and used in MSP reactions. Figure 1d shows representative MSP data obtained from seven breast tumor samples. In tumor samples BrCaT8, 12 and 16 (Figure 1d, lanes 9-14) , we observed amplification with only the unmethylated-specific primer set indicating a lack of ATM promoter hypermethylation in these tumor samples. Tumor samples BrCaT2, 14, 20 and 23 (Figure 1d, lanes 1-8) show amplification with both unmethylated-and methylatedspecific primer sets. (Amplification of both unmethylated-and methylated-specific MSP products is a common finding during the analysis of tumor samples (Herman et al., 1996) potentially attributable to contamination of the tumor sample with normal cells and/or heterogeneous promoter methylation within the tumor cell population.) Of the 23 tumors analysed in this study, we found that 18 (78%) displayed aberrant methylation of the ATM promoter as judged by MSP, indicating that this is a common event in locally advanced breast malignancies. MSP analysis conducted on bisulfite-modified gDNA harvested from primary cultures of human mammary epithelial cells (HMEC) indicated that the ATM promoter is unmethylated in this cell line (Figure 1d, lanes 15 and 16) .
As an independent means of assessing ATM promoter methylation, bisulfite-modified gDNA from several breast tumors were analysed by sequencing an amplicon (designated Seq 2) obtained using primers designed to amplify a segment of the ATM promoter in a methylation-independent manner. Specifically, PCR primers were designed to regions of the ATM promoter devoid of CpG dinucleotides; thus, amplification proceeds in a manner unbiased by promoter methylation status. Amplicons were subsequently subcloned and subjected to automated DNA sequencing and these sequences were compared to nonmodified ATM promoter sequence and the methylation status of CpG dinucleotides determined by characteristic chemical changes associated with cytosines existing in either a methylated or unmethylated state prior to bisulfite treatment (Figure 2a ). Tumors BrCaT8 (Figure 2b ) and 16 (Figure 2c ), which harbor unmethylated ATM promoter as judged by MSP, showed no CpG methylation when cloned Seq 2 amplicon was analysed by sequencing. Alternatively, tumors BrCaT7 (Figure 2d ) and 20 (Figure 2e) , both of which are MSP positive, displayed positive methylation of all CpG within the region analysed. Thus, bisulfite sequencing of gDNA confirms our MSP analysis and indicates that the ATM promoter is a target for aberrant methylation in advanced breast cancer.
Current views hold that epigenetic silencing of gene expression stems from dense methylation of CpG dinucleotides within gene promoter regions (Jones and Baylin, 2002) . To determine the density of CpG methylation within the ATM promoter, we cloned partially overlapping PCR fragments (Figure 3a) obtained from amplification of bisulfite-modified gDNA harvested from breast tumors obtained using primer sets which amplify regions of the ATM promoter in a methylation-independent manner. We analysed the MSP-positive tumors BrCaT3, 7 and 20, and the MSP-negative tumor BrCaT16. Following PCR, Seq 2 and Seq 3 amplicons were subsequently subcloned, multiple recombinants identified and analysed by automated sequencing.
We observed saturating methylation of all 26 CpG dinucleotides within this 266 bp region of the ATM promoter in tumor BrCaT20 (Figure 3b ). In BrCaT7, many of the CpG displayed saturating methylation, while subsaturating methylation was detected at all other CpG within this region. In clones obtained from BrCaT3, we observed no CpG displaying saturating methylation; however, the majority of CpGs within these amplicons showed observable methylation. In the MSP-negative BrCa16 tumor, we observed no CpG methylation. The results of this experiment clearly indicate that significant portions of the ATM promoter are subject to dense methylation in breast tumors. Moreover, as is the case in gDNA harvested from tumors BrCa20 and 7, methylated ATM promoter may be the predominant species within pools of gDNA harvested from locally advanced breast tumors.
Finally, we sought to determine if aberrant methylation of the ATM proximal promoter region leads to reduced expression of the ATM gene. To conduct this analysis, we used quantitative, real-time RT-PCR (Q-PCR). Primers designed for RT-PCR amplification of the ATM transcript span exons 3 and 4 of the ATM gene (Figure 4a ). cDNA synthesized from total RNA harvested from manually microdissected breast tumor samples was used in an RT-PCR reaction and we observed amplification of the ATM transcript in cDNA reactions conducted in the presence of reverse transcriptase (Figure 4b, lane 1) but not in the absence of reverse transcriptase (Figure 4b, lane 2) , indicating the transcript-dependent nature of amplification.
Q-PCR was conducted using a TaqMan s probe design. Thermocycle threshold (C t ) values for ATM and GUS (b-glucuronidase) transcripts were measured and relative ATM expression as a function of GUS transcript abundance was calculated. Relative ATM transcript abundance was measured in our panel of 23 breast tumors and cultured HMEC. Q-PCR analysis revealed that 15 (65%) of these tumors displayed diminished expression (X3-fold) of ATM mRNA compared to HMEC (Figure 4c) . Several of the tumors assayed showed ATM transcript abundance closely approximating that measured in HMEC underscoring the utility of these cultured cells as a control in this assay.
Strikingly, when MSP results obtained on this panel of tumors were merged with the results of our Q-PCR analysis, we observed a highly significant (P ¼ 0.0006) statistical correlation between reduced (X3-fold) ATM mRNA abundance and aberrant methylation of the ATM proximal promoter region. Moreover, all 15 of the breast tumors that exhibit X3-fold reduction of ATM mRNA compared to HMECs display aberrant methylation of the ATM promoter region.
In sum, our findings conclusively demonstrate that the proximal promoter region of the ATM gene is a target for aberrant methylation in locally advanced sporadic breast cancer and that this event has a high likelihood of resulting in reduced ATM gene expression. It bears consideration that, in our study cohort, two tumors (BrCaT1 and BrCaT8) display X2-fold reduced ATM mRNA expression (relative to HMEC) without detectable ATM promoter hypermethylation. Conversely, one tumor (BrCaT15) that was found to harbor methylated ATM promoter as judged by MSP exhibits only a modest reduction in ATM mRNA abundance. Others have observed that, in some cell types, ionizing radiation or growth factors can exert effects on ATM gene expression through alterations in rates of gene transcription (Fang et al., 2001; Gueven et al., 2001) . Although the ATM promoter contains several canonical Figure 2 ) and a second primer set that also amplifies a segment (designated Seq 3) of the ATM promoter in a methylation-independent manner. Seq 3 primers are 5 0 -AATGTTTTGGGGTAGTGTTTTG-3 0 (sense) and 5 0 -CCCACTTCTAAAAAAAAAAAC-3 0 (antisense), and amplify a 106 bp segment (nt À313 to À207). Collectively, these primers amplify two partially overlapping fragments of the ATM promoter that span a 266 bp region of the genome. (b) Seq 2 and Seq 3 amplicons from each indicated tumor were subcloned, recombinant clones identified by restriction mapping and sequenced using plasmid-encoded primers. From each tumor sample, X10 individual recombinant clones of each amplicon were analysed. The percentage of clones showing methylation at each of the 26 CpG dinucleotides within the analysed 266 bp of the ATM promoter is indicated transcription factor recognition motifs (Byrd et al., 1996; Gueven et al., 2003) , little is known regarding the mechanisms that control ATM gene expression. Thus, while our findings firmly indicate a tight relationship between aberrant methylation of the ATM promoter and reduced gene expression, other factors could potentially alter expression of this gene in breast tumors.
Aberrant methylation of CpG dinucleotides is an epigenetic phenomenon that has dramatic effects on gene expression. In cancer, many key tumor suppressor genes are subjected to epigenetic silencing and this process is now widely recognized as either a causative or correlative event in tumor development (Jones and Baylin, 2002) . It is thus unsurprising that a list of wellcharacterized tumor suppressors including BRCA1, p16
INK4a and E-cadherin are known to be targets for epigenetic silencing in breast cancer (Esteller et al., 2001 ). While we are currently unsure when the ATM promoter undergoes hypermethylation during the process of breast tumorigenesis, our findings clearly indicate that this gene is targeted for silencing in advanced stages of sporadic breast cancer. Given the important role that ATM plays in the maintenance of genome stability, it is logical that reduced ATM expression would potentially be an important event in tumor initiation and/or progression. Finally, our findings establish a molecular mechanism that potentially connects diminished ATM function with sporadic breast cancer. (c) For quantitative real-time PCR, a firststrand synthesis (cDNA) reaction was synthesized from total RNA harvested from breast tumor using random hexamer primers. cDNA was subsequently used in PCR reactions containing 50 nM TaqMan probe (5 0 -FAM-AGCCTGCAGACCTTCATGTCCTG-CA-TAMRA-3 0 ) and thermocycling carried out on an ABI Prism 7700 Sequence Detector. In parallel reactions, b-glucuronidase (GUS) transcript abundance was measured using a commercially available Q-PCR assay (ABI cat# Hs99999908_m1). ATM transcript abundance, as a function of GUS transcript abundance, was measured and relative ATM mRNA expression in each was calculated relative to HMEC ATM mRNA abundance. Graphed is the mean of at least two independent measurements and each experiment was conducted in triplicate. Standard deviation for all samples is o0.2%; hence, error bars were omitted from the graph. Dotted line denotes threefold reduced ATM mRNA abundance compared to HMEC, M denotes tumors displaying ATM promoter methylation as determined by MSP analysis. The statistical relationship between relative ATM expression and ATM promoter methylation was calculated by Fisher's exact test using SAS software This work was supported by grants from the NIH (R21 CA102220), the A-T Children's Project and the Louisiana Breast Cancer Task Force/Cancer Association of Greater New Orleans to KDB. QNV was supported, in part, by a postdoctoral fellowship from the Stanley S Scott Cancer Center.
